Company: PMVP
Filing Date: 2025-09-10
Form Type: 8-K
Source: 0001193125-25-199857
Chunk: 1

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-09-10
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01      Other Events.  

On September 10, 2025, PMV Pharmaceuticals, Inc. (the “ Company”) issued a press release announcing rezatapopt monotherapy interim data from its PYNNACLE Phase 2 trial across multiple solid tumors with a TP53 Y220C mutation and hosted an investor webinar to review the Phase 2 interim clinical data. The press release is attached hereto as Exhibit 99.2 and incorporated by reference herein.

The press release attached as Exhibit 99.2 to this Current Report on Form8-Kincludes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.